Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma

NCT02944812 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG: Chidamide

Sponsor

Guangdong Provincial People's Hospital